We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current TARS market cap is 1.78B. The company's latest EPS is USD -3.0110 and P/E is -15.45.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 13.08M | 27.61M | 40.81M | 48.12M | 66.41M |
| Operating Income | -44.45M | -37.68M | -33.3M | -25.16M | -24.42M |
| Net Income | -41.9M | -35.73M | -33.29M | -23.42M | -23.11M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 57.03M | 25.82M | 17.45M | 182.95M |
| Operating Income | -27M | -12.16M | -62.71M | -143.16M | -120.57M |
| Net Income | -26.81M | -13.83M | -62.09M | -135.89M | -115.55M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 265.49M | 349.28M | 376.84M | 376.3M | 376.99M |
| Total Liabilities | 68.5M | 74.07M | 124.6M | 138.82M | 152.46M |
| Total Equity | 196.99M | 275.21M | 252.25M | 237.48M | 224.53M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 171.97M | 178.91M | 227.86M | 265.49M | 376.99M |
| Total Liabilities | 5.99M | 12.18M | 34.96M | 68.5M | 152.46M |
| Total Equity | 165.98M | 166.73M | 192.9M | 196.99M | 224.53M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -117.49M | -37.79M | -52.19M | -60.85M | -83.03M |
| Investing | 140.6M | -102.22M | -142.75M | -139.62M | -199.2M |
| Financing | 130.18M | 108.77M | 151.09M | 151.73M | 154.66M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -21.14M | 3.75M | -49.03M | -117.49M | -83.03M |
| Investing | -456k | -586k | -144.63M | 140.6M | -199.2M |
| Financing | 131.77M | 21k | 93.99M | 130.18M | 154.66M |
| Market Cap | 1.78B |
| Price to Earnings Ratio | -15.45 |
| Price to Sales Ratio | 9.76 |
| Price to Cash Ratio | 18.83 |
| Price to Book Ratio | 7.95 |
| Dividend Yield | - |
| Shares Outstanding | 38.38M |
| Average Volume (1 week) | 529.32k |
| Average Volume (1 Month) | 655.67k |
| 52 Week Change | 52.46% |
| 52 Week High | 57.28 |
| 52 Week Low | 20.0818 |
| Spread (Intraday) | 3.58 (7.37%) |
| Company Name | Tarsus Pharmaceuticals Inc |
| Address |
3500 s dupont hwy dover, delaware 19901 |
| Website | https://www.tarsusrx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
